General Information of Drug (ID: DMCM5GK)

Drug Name
TAK-070 Drug Info
Synonyms
UNII-PNM9E64544; PNM9E64544; TAK-070; (2R)-N,N-Dimethyl-6-(4-biphenylylmethoxy)-1,2,3,4-tetrahydronaphthalene-2alpha-ethanamine; TAK-070 free base; N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine; N,N-Dimethyl-2-((2R)-6-((4-phenylphenyl)methoxy)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine; SCHEMBL361018; GTPL6940; 212571-56-7; J3.229.705F; 2-((2R)-6-(4-Biphenylylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl)-N,N-dimethylethanamine; 2-Naphthaleneethanamine, 6-((1,1'-biphenyl)-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Clinical trial [1]
Cross-matching ID
PubChem CID
23519711
CAS Number
CAS 365276-12-6
TTD Drug ID
DMCM5GK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Beta-secretase (BACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [2]
E-2609 DMTNUJ8 Alzheimer disease 8A20 Phase 3 [3]
verubecestat DM4CGH5 Alzheimer disease 8A20 Phase 3 [4]
Lanabecestat DMFJLB6 Alzheimer disease 8A20 Phase 3 [5]
AZD3293 DMJQHXD Alzheimer disease 8A20 Phase 2/3 [6]
JNJ-54861911 DMGPJ5U Alzheimer disease 8A20 Phase 2/3 [5]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [2]
LY2886721 DMV14LM Alzheimer disease 8A20 Phase 2 [7]
LY3202626 DM7IFNB Alzheimer disease 8A20 Phase 2 [5]
AZD-3839 DM72FOD Alzheimer disease 8A20 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [1]

References

1 A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66.
2 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
3 Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
4 BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
7 Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
8 Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.